Viatris Fined $1.9 Million Over Alleged Violation of Antitrust Restrictions

MT Newswires Live11-22

Viatris (VTRS) has been fined 1.5 million UK pounds ($1.9 million) by the UK's Competition and Markets Authority for failing to comply with an order obtaining government approval before making staff changes and failing to report the breach, the regulator said Friday.

The penalty was imposed in response to Viatris' sale of the European right to its hormone replacement therapy treatments Duphaston and Femoston to Theramex, which the regulator said could reduce competition.

The regulator said Viatris breached restrictions imposed on it during an investigation by "implementing changes to key members of its UK management team" without consent and failing to notify authorities of the breach.

Viatris did not immediately reply to MT Newswires' request for comment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment